Alector Reports Q4 Revenue of $6.2M, Beating Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Should l Buy ALEC?
Reports Q4 revenue $6.2M, consensus $1.96M. "Alector's strength lies in the combination of a highly differentiated blood-brain barrier platform and a team with deep experience executing complex neurodegenerative programs," said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. "Following more than six years of focused investment in our ABC technology, we believe the breadth, flexibility, and tunability of our ABC platform position us to translate scientific innovation into exciting clinical-stage assets. At the same time, we continue to advance the PROGRESS-AD Phase 2 trial of nivisnebart in early Alzheimer's disease, together with GSK, toward an independent interim futility analysis in the first half of 2026."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALEC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALEC
Wall Street analysts forecast ALEC stock price to fall
8 Analyst Rating
1 Buy
5 Hold
2 Sell
Hold
Current: 2.190
Low
0.90
Averages
2.10
High
5.00
Current: 2.190
Low
0.90
Averages
2.10
High
5.00
About ALEC
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alector Shares Surge 15% After Upgrade to Buy by BRIG
- Upgrade Impact: Alector shares rose approximately 15% following BRIG's upgrade from Neutral to Buy, indicating positive market sentiment towards the company's strategic pivot towards its blood-brain barrier technology platform.
- Strategic Shift: After a late-stage trial setback for the dementia treatment latozinemab developed with GSK, Alector announced a resource reallocation to its BBB technology platform, Alector Brain Carrier, reflecting a reassessment of its future therapeutic strategies.
- Workforce Reduction and Project Adjustments: The failure of the INFRONT-3 clinical trial forced Alector to cut nearly 49% of its workforce and halt the open-label extension of INFRONT-3 and the continuation study for latozinemab, which, while impacting operations in the short term, allows for a focused approach moving forward.
- Analyst Optimism: BTIG analyst Thomas Shrader noted that Alector's new direction alleviates concerns following the FTD trial failure, setting a new price target of $6 per share, suggesting a bullish outlook on the company's future developments.
See More
Latest Wall Street Rating Updates
- BofA Downgrades Qualcomm: Bank of America has downgraded Qualcomm from neutral to underperform with a price target of $145, citing lukewarm projected sales and EPS growth of only 2% and 1% CAGR from 2025 to 2028, significantly lagging the semiconductor sector's expected 17% growth.
- Deutsche Bank Upgrades Teladoc: Deutsche Bank upgraded Teladoc from hold to buy, highlighting an attractive risk/reward profile due to compelling valuation and a deliverable strategy for its BetterHelp business, indicating a strong potential for future growth.
- TD Cowen Upgrades Rivian: TD Cowen upgraded Rivian from hold to buy, projecting full-scale demand for its R2 model to reach between 212,000 and 335,000 units, suggesting significant upside potential against 2027 consensus estimates.
- Morgan Stanley Reiterates Microsoft Overweight: Morgan Stanley reiterated its overweight rating on Microsoft, emphasizing the readiness of its Office product suite for the upcoming Agentic AI offerings, with general availability expected on May 1, 2026, priced at $99 per user per month.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Upgrades and Downgrades: The rating changes include upgrades and downgrades for certain stocks, prompting investors to pay attention to these shifts to assess potential investment opportunities and risks.
- Market Reaction Expectations: Analysts' rating adjustments may lead to short-term volatility in the affected stocks, necessitating investors to closely monitor market dynamics to seize investment opportunities.
- Information Source: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing crucial insights for investor decision-making.
See More
Alector Showcases ABC Brain-Delivery Platform Progress
- ABC Platform Advantage: Alector's ABC platform utilizes the side epitope of the transferrin receptor (TfR) to achieve over a 12-fold increase in cerebrospinal fluid (CSF) levels in non-human primates, significantly enhancing drug uptake in the brain while reducing Fc-mediated safety risks, showcasing its potential in treating neurodegenerative diseases.
- AL137 Clinical Progress: AL137, an anti-amyloid antibody enabled by ABC technology, achieved approximately 30-fold higher brain tissue uptake in non-human primates and demonstrated good tolerability at a 3 mg/kg therapeutic dose, with an IND filing expected by year-end and plans for rapid initiation of first-in-human trials.
- Innovation in AL050: Alector's AL050 program features an engineered glucocerebrosidase (GCase) with 50 times the activity of wild-type, showing significant increases in brain enzymatic activity in non-human primates, indicating promising applications for treating GBA-associated Parkinson's disease and Lewy body dementia.
- siRNA Delivery Capability: Alector's siRNA program leverages ABC technology for peripheral dosing, with non-human primate studies demonstrating up to 70% tau mRNA knockdown across brain regions and no adverse events observed, highlighting its broad application potential in neurodegenerative disease treatment.
See More
Alector Reports Q4 Earnings Amidst Challenges
- Earnings Report: Alector reported a Q4 GAAP EPS of -$0.34 and revenue of $6.2 million, indicating financial strain amidst ongoing challenges that may undermine investor confidence.
- Drug Development Setback: The failure of Latozinemab has led to a decline in Alector's stock price, reflecting market concerns over its drug pipeline and potentially complicating future financing efforts.
- Executive Appointment: Alector appointed Neil Berkley as CFO, aiming to enhance financial management capabilities through new leadership to navigate current market challenges and strategic adjustments.
- Investor Focus: Alector's presentation at the BofA Securities CNS Therapeutics Virtual Conference garnered attention, with investors looking forward to updates from its Phase 2 clinical trials to restore market confidence.
See More
Alector's Phase 3 Trial Results Fail to Meet Expectations
- Trial Results: Alector's Phase 3 INFRONT-3 trial evaluating latozinemab showed that while the biomarker response met expectations, the clinical co-primary endpoint was not achieved, leading to investor disappointment.
- Participant Demographics: The trial enrolled 119 patients, including 103 symptomatic FTD-GRN individuals and 16 at-risk carriers, with a mean age of 62.1 years, indicating the drug's potential application in a specific demographic.
- Market Reaction: Following the mixed trial results, analysts downgraded Alector's stock, reflecting market concerns about its biotech operations, which may impact the company's future financing capabilities.
- Legal Investigation: Levi & Korsinsky, LLP is investigating Alector, highlighting investor concerns regarding the company's operational performance, which could lead to further legal actions.
See More
Alector Shares Surge 15% After Upgrade to Buy by BRIG
- Upgrade Impact: Alector shares rose approximately 15% following BRIG's upgrade from Neutral to Buy, indicating positive market sentiment towards the company's strategic pivot towards its blood-brain barrier technology platform.
- Strategic Shift: After a late-stage trial setback for the dementia treatment latozinemab developed with GSK, Alector announced a resource reallocation to its BBB technology platform, Alector Brain Carrier, reflecting a reassessment of its future therapeutic strategies.
- Workforce Reduction and Project Adjustments: The failure of the INFRONT-3 clinical trial forced Alector to cut nearly 49% of its workforce and halt the open-label extension of INFRONT-3 and the continuation study for latozinemab, which, while impacting operations in the short term, allows for a focused approach moving forward.
- Analyst Optimism: BTIG analyst Thomas Shrader noted that Alector's new direction alleviates concerns following the FTD trial failure, setting a new price target of $6 per share, suggesting a bullish outlook on the company's future developments.
See More
Latest Wall Street Rating Updates
- BofA Downgrades Qualcomm: Bank of America has downgraded Qualcomm from neutral to underperform with a price target of $145, citing lukewarm projected sales and EPS growth of only 2% and 1% CAGR from 2025 to 2028, significantly lagging the semiconductor sector's expected 17% growth.
- Deutsche Bank Upgrades Teladoc: Deutsche Bank upgraded Teladoc from hold to buy, highlighting an attractive risk/reward profile due to compelling valuation and a deliverable strategy for its BetterHelp business, indicating a strong potential for future growth.
- TD Cowen Upgrades Rivian: TD Cowen upgraded Rivian from hold to buy, projecting full-scale demand for its R2 model to reach between 212,000 and 335,000 units, suggesting significant upside potential against 2027 consensus estimates.
- Morgan Stanley Reiterates Microsoft Overweight: Morgan Stanley reiterated its overweight rating on Microsoft, emphasizing the readiness of its Office product suite for the upcoming Agentic AI offerings, with general availability expected on May 1, 2026, priced at $99 per user per month.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Upgrades and Downgrades: The rating changes include upgrades and downgrades for certain stocks, prompting investors to pay attention to these shifts to assess potential investment opportunities and risks.
- Market Reaction Expectations: Analysts' rating adjustments may lead to short-term volatility in the affected stocks, necessitating investors to closely monitor market dynamics to seize investment opportunities.
- Information Source: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing crucial insights for investor decision-making.
See More
Alector Showcases ABC Brain-Delivery Platform Progress
- ABC Platform Advantage: Alector's ABC platform utilizes the side epitope of the transferrin receptor (TfR) to achieve over a 12-fold increase in cerebrospinal fluid (CSF) levels in non-human primates, significantly enhancing drug uptake in the brain while reducing Fc-mediated safety risks, showcasing its potential in treating neurodegenerative diseases.
- AL137 Clinical Progress: AL137, an anti-amyloid antibody enabled by ABC technology, achieved approximately 30-fold higher brain tissue uptake in non-human primates and demonstrated good tolerability at a 3 mg/kg therapeutic dose, with an IND filing expected by year-end and plans for rapid initiation of first-in-human trials.
- Innovation in AL050: Alector's AL050 program features an engineered glucocerebrosidase (GCase) with 50 times the activity of wild-type, showing significant increases in brain enzymatic activity in non-human primates, indicating promising applications for treating GBA-associated Parkinson's disease and Lewy body dementia.
- siRNA Delivery Capability: Alector's siRNA program leverages ABC technology for peripheral dosing, with non-human primate studies demonstrating up to 70% tau mRNA knockdown across brain regions and no adverse events observed, highlighting its broad application potential in neurodegenerative disease treatment.
See More
Alector Reports Q4 Earnings Amidst Challenges
- Earnings Report: Alector reported a Q4 GAAP EPS of -$0.34 and revenue of $6.2 million, indicating financial strain amidst ongoing challenges that may undermine investor confidence.
- Drug Development Setback: The failure of Latozinemab has led to a decline in Alector's stock price, reflecting market concerns over its drug pipeline and potentially complicating future financing efforts.
- Executive Appointment: Alector appointed Neil Berkley as CFO, aiming to enhance financial management capabilities through new leadership to navigate current market challenges and strategic adjustments.
- Investor Focus: Alector's presentation at the BofA Securities CNS Therapeutics Virtual Conference garnered attention, with investors looking forward to updates from its Phase 2 clinical trials to restore market confidence.
See More
Alector's Phase 3 Trial Results Fail to Meet Expectations
- Trial Results: Alector's Phase 3 INFRONT-3 trial evaluating latozinemab showed that while the biomarker response met expectations, the clinical co-primary endpoint was not achieved, leading to investor disappointment.
- Participant Demographics: The trial enrolled 119 patients, including 103 symptomatic FTD-GRN individuals and 16 at-risk carriers, with a mean age of 62.1 years, indicating the drug's potential application in a specific demographic.
- Market Reaction: Following the mixed trial results, analysts downgraded Alector's stock, reflecting market concerns about its biotech operations, which may impact the company's future financing capabilities.
- Legal Investigation: Levi & Korsinsky, LLP is investigating Alector, highlighting investor concerns regarding the company's operational performance, which could lead to further legal actions.
See More
